For research use only. Not for therapeutic Use.
Abelacimab（Cat No.:I042188）is an investigational monoclonal antibody designed to target and inhibit both tissue factor (TF) and factor Xa, key components involved in the coagulation cascade. By binding to tissue factor, abelacimab aims to prevent the initiation of blood clotting, while inhibiting factor Xa interferes with the amplification of the clotting process. This dual-target approach is intended to provide enhanced anticoagulation with a potentially lower risk of bleeding compared to traditional anticoagulants. Abelacimab is being studied in clinical trials for its potential to treat patients with venous thromboembolism and other clotting disorders.
| Catalog Number | I042188 |
| CAS Number | 2098724-83-3 |
| Purity | ≥95% |
